SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market navigates potential rate cuts and traders assess bullish vs. bearish signals. Community members are actively discussing potential price movements and one upcoming network upgrade. There is also significant spam and user disputes dominating the message boards.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid community discussions around new projects like SUPERLIQUID and WEEDCOIN building on the network. Some traders are speculating about potential price movements and identifying key support levels. However, the SOL board is also experiencing significant spam and reports of user scams, creating a divided community atmosphere.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is seeing active discussion around potential AI overvaluation concerns, despite positive earnings from Nvidia. Community members are debating whether this dip presents a buying opportunity or signals a larger correction, while also pointing to European market activity and negative interest rates in DeFi as influencing factors. Traders are closely watching key support and resistance levels amid volatility and upcoming economic data releases.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending amid discussions around its Q3 earnings, which beat expectations, and reaffirmed its full-year outlook, while also discussing the future of the F-150 Lightning. The community is weighing the impact of these factors, as well as potential policy changes, on Ford's financial targets and production strategy. Some traders are noting the stock's technical setup and eyeing potential short-term pullbacks after the recent surge.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WRD is trending as traders discuss its potential following news of Switzerland's first driverless robotaxi permit and institutional put/call sentiment. Bullish community members speculate on leaked earnings and expansion into new markets like Switzerland and Japan. However, some investors remain cautious, citing concerns about the company's financials and competitive landscape, drawing comparisons to competitor PONY.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as community members rally around this OG meme coin, emphasizing its strong community, organic growth, and potential for significant returns. Active discussions revolve around its unique position in meme culture and the belief that it's more than just a coin, but a movement. The community is focused on building and expanding across multiple social media platforms.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending as traders discuss options activity and potential upside, particularly around call options with various expiration dates and strike prices. The community is also evaluating the company's growth prospects, pipeline developments, and potential acquisitions, while legal liabilities related to talc are still a concern for some investors. Some analysts anticipate JNJ being involved in potential mergers and acquisitions, particularly for companies like Protagonist Therapeutics.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors discuss its potential to join the trillion-dollar market cap club amid positive analyst outlooks and expected sales growth. Community members are weighing in on AI's impact, the health of the market, and potential opportunities for AMD in comparison to competitors. Semiconductor supply chain developments and potential impacts of trade policies are also being closely monitored.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to upcoming Phase 3 data being presented at a conference, sparking discussions of a potential short squeeze and comparisons to other high-flying stocks with similar ownership structures. Community members are highlighting the company's low share float, high institutional ownership, and the potential for buyout interest. Some caution is being urged due to the company's history and potential dilution.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI (PONY) is trending due to positive analyst coverage and permits for robotaxi services, sparking community discussion about its growth potential in the autonomous vehicle market. Investors are weighing its prospects against competitors and monitoring upcoming earnings. Speculation swirls around its ability to maintain momentum and achieve profitability amidst market volatility.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CFO Jason O'byrne sold 6,799 shares of Vir Biotechnology stock in a transaction on Monday, November 17th. The stock was sold at an average price...

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare...

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.</li><li>Gilead’s rival therapy bulevirtide remains the only approved hepatitis delta treatment in Europe but showed lower long-term response rates in earlier studies.</li><li>VIR trended on Stocktwits as traders highlighted strong efficacy, Gates Foundation backing, and potential for a future head-to-head Phase 3 matchup with Gilead.</li></ul>Vir Biotechnology drew heightened retail attention on Sunday after unveiling new Phase 2 data showing its tobevibart-elebsiran combination achieved high rates of undetectable hepatitis delta virus (HDV) RNA, positioning the therapy as a potential rival to Gilead Sciences’ bulevirtide, which is currently the only approved HDV treatment in Europe.<h2 class="st-heading-2">Vir’s Combination Delivers Strong 48-Week Results</h2>Vir said 66% of participants in its Phase 2 SOLSTICE trial receiving monthly doses of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48, while 90% showed reductions in hepatitis B surface antigen below 10 IU/mL, a marker of suppressed viral replication. Alanine aminotransferase levels normalized in more than half of the participants.The dual regimen was well-tolerated, with no grade 3 or higher treatment-related adverse events or discontinuations. The company said results were consistent even in patients with cirrhosis and high baseline viral load.“Achieving undetectable HDV RNA is a key endpoint in clinical trials, and HDV RNA undetectability is associated with better outcomes for people living with chronic hepatitis delta,” said Tarik Asselah, of the University of Paris-Cité, who presented the data at AASLD’s The Liver Meeting in Washington, D.C.<h2 class="st-heading-2">Eclipse Registration Program Advances</h2>Vir said the combination is now being evaluated in its Eclipse global Phase 3 program, comprising three randomized, controlled trials. Eclipse-1 has completed enrollment ahead of schedule, with topline results from Eclipse-1, -2 and -3 expected in the first quarter of 2027.CEO Marianne De Backer said the new 48-week data “reinforce our confidence that a monthly dose of tobevibart and elebsiran can deliver meaningful patient benefit with convenient dosing.”According to the company, the combination offers the potential to eliminate the virus by tackling the viral lifecycle through multiple mechanisms.<h2 class="st-heading-2">Gilead’s Bulevirtide Demonstrates Durable Off-Treatment Control</h2>In May, Gilead Sciences reported final results from its pivotal Phase 3 MYR301 study showing that 36% of adults treated with bulevirtide maintained virologic suppression for almost two years after stopping therapy. Participants who remained undetectable for one year post-treatment experienced no relapses in the second year of follow-up.Among those with prolonged viral clearance at 96 weeks or later, 90% remained undetectable off-treatment.Gilead said the data underscore bulevirtide’s durability after treatment cessation and the importance of sustained viral suppression during therapy. Bulevirtide 2 mg is the only approved HDV therapy in the EEA, UK, Switzerland, and Australia and is not approved in the U.S.<h2 class="st-heading-2">Stocktwits Traders See ‘Phenomenal’ Data</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the top ten trending stocks on the platform.<figure class="image"><img style="aspect-ratio:968/142;" src="https://news.stocktwits-cdn.com/vir_ss_jpg_558bd7efe5.webp" alt="vir ss.jpg" width="968" height="142"><figcaption>VIR sentiment and message volume as of November 9 | Source: Stocktwits</figcaption></figure>One user noted that they were encouraged by the company’s strong trial results and high-profile early backers, including the Gates Foundation and Cathie Wood’s ARK Invest, calling the data “phenomenal” and suggesting pre-market trading could reflect the momentum.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635536553</stembedurl>Another investor commented that the trial outcomes appeared “extremely strong,” adding that those who entered the stock before the weekend “may reap rewards” depending on market reaction.<stembedurl>https://stocktwits.com/TDMF123/message/635536478</stembedurl>A third user compared the 66% undetectable HDV RNA rate achieved with Vir’s monthly regimen to what they said was roughly 16% efficacy for Gilead’s bulevirtide, which requires daily injections, describing the results as “good news” ahead of eventual head-to-head Phase 3 testing.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635535478</stembedurl><a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology’s stock</a> has declined 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vir Biotechnology’s stock has declined 30% so far in 2025. (Photo credit: Getty Images)

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown

Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.

Equity

Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Companys Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants...

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,385 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the company's stock in a transaction dated Wednesday, November 5th. The shares were sold at an...

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday...

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.47 EPS

Vir Biotechnology (NASDAQ:VIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of...

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

VIR
Vir Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VIR News

VIRVir Biotechnology Inc